• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

BMC Infect Dis . The development and implementation of a proficiency testing program for SARS-CoV-2 using dried tube specimens in resource-limited

tetano

Editor, Senior Moderator
BMC Infect Dis


. 2024 Jun 27;24(1):646.
doi: 10.1186/s12879-024-09555-y. The development and implementation of a proficiency testing program for SARS-CoV-2 using dried tube specimens in resource-limited countries

Pius Lutaaya[SUP] 1 [/SUP], Ocung Guido[SUP] 2 [/SUP], Hasifah Nakato Ssentamu[SUP] 2 [/SUP], George William Kasule[SUP] 2 [/SUP], Mary Akumu[SUP] 2 [/SUP], Jupiter Marina Kabahita[SUP] 2 [/SUP], Bernard Bagaya[SUP] 2 [/SUP], Kenneth Musisi[SUP] 2 [/SUP], Denis Oola[SUP] 2 [/SUP], Anitah Katuramu[SUP] 2 [/SUP], Andrew Nsawotebba[SUP] 2 [/SUP], Edgar Kigozi[SUP] 3 [/SUP], Faith Nakazzi[SUP] 3 [/SUP], Joel Kabugo Solomon[SUP] 2 [/SUP], Isa Adam[SUP] 2 [/SUP], Orena Beatrice[SUP] 2 [/SUP], Joanita Namutebi[SUP] 2 [/SUP], Brenda Ayebare[SUP] 3 [/SUP], Abdunoor Nyombi[SUP] 2 [/SUP], Charles Manyonge[SUP] 2 [/SUP], Ademun Julius Patrick[SUP] 2 [/SUP], Kangave Fredrick[SUP] 2 [/SUP], Moses L Joloba[SUP] 2 3 [/SUP]



Affiliations
Abstract

Introduction: When COVID-19 hit the world in 2019, an enhanced focus on diagnostic testing for SARS-CoV-2 was essential for a successful pandemic response. Testing laboratories stretched their capabilities for the new coronavirus by adopting different test methods. The necessity of having external quality assurance (EQA) mechanisms was even more critical due to this rapid expansion. However, there was a lack of experience in providing the necessary SARS-CoV-2 EQA materials, especially in locations with constrained resources.
Objective: We aimed to create a PT (Proficiency testing) programme based on the Dried Tube Specimens (DTS) method that would be a practical option for molecular based SARS-CoV-2 EQA in Low- and Middle-Income Countries.
Methods: Based on previous ISO/IEC 17043:2010 accreditation experiences and with assistance from the US Centers for Disease Control and Prevention, The Supranational Reference Laboratory of Uganda (adapted the DTS sample preparation method and completed a pilot EQA program between 2020 and 2021. Stability and panel validation testing was conducted on the designed materials before shipping to pilot participants in six African countries. Participants received a panel containing five SARS-CoV-2 DTS samples, transported at ambient conditions. Results submitted by participants were compared to validation results. Participants were graded as satisfactory (≥ 80%) or unsatisfactory (< 80%) and performance reports disseminated.
Results: Our SARS-CoV-2 stability experiments showed that SARS-CoV-2 RNA was stable (-15 to -25 °C, 4 to 8 °C, (18 to 28 °C) room temperature and 35 to 38 °C) as well as DTS panels (4 to 8 °C, 18 to 28 °C, 35 to 38 °C and 45 °C) for a period of 4 weeks. The SARS-CoV-2 DTS panels were successfully piloted in 35 test sites from Zambia, Malawi, Mozambique, Nigeria, and Seychelles. The pilot results of the participants showed good accuracy, with an average of 86% (30/35) concordance with the original SARS CoV-2 expectations.
Conclusion: The SARS-CoV-2 DTS PT panel is reliable, stable at ambient temperature, simple to prepare and requires minimal resources.

Keywords: Dried tube specimens; External quality assessment; Proficiency testing; SARS-CoV-2.

 
Back
Top Bottom